Epigenomics, DPC Lebanon Ink Pact to Distribute Colorectal Cancer MDx in Middle East | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today announced an exclusive agreement with DPC Lebanon for the distribution of the Epi proColon colorectal cancer test in parts of the Middle East.

Under the agreement, DPC Lebanon will distribute the test for the early detection of colorectal cancer in blood in Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Syria, Jordan, and Egypt.

Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.